“The Relationship of Mean Platelet Volume with Endogenous Sex Hormones and Cardiovascular Risk Parameters In Postmenopausal Women ‘’

Year 2014, Volume: 19 Issue: 1, 28 - 32, 29.04.2014

Nilgün Güdücü , Salih Kutay Güliz Sidar Uzay Görmüş Zehra Kavak İlkkan Dünder

Abstract

ABSTRACT

Aims: Evaluation of the relationship among mean platelet volume (MPV) and endogenous sex hormones and cardiovascular (CV) risk parameters

Methods: We designed a retrospective study in postmenopausal women. Patient charts were reviewed for the results of mean platelet volume, hormonal and biochemical parameters.

Results: MPV correlated only with white blood cell and platelet counts(r = -0.270, p = 0.023) and platelet count (r = -0.558, p = 0.001). There was no statistically significant difference in MPV of patients with and without metabolic syndrome.

Conclusion: There was no relationship between MPV and endogenous sex hormones and parameters indicating higher CV risk.

Keywords

Endogenous sex hormones, postmenopausal women, mean platelet volume, cardiovascular disease

References

• Stampfer MJ, Willett WC, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and coronary artery disease. N Engl J Med 1985; 313: 1044-1049.
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
• Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84: 6136
• Chu SG, Becker RC, Berger PB, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and metaanalysis. J Thromb Haemost 2010; 8: 148-156.
• Martin JF, Trowbridge EA, Salmon G, Plumb J. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res 1983; 32: 443-460.
• Khetwat G, Farday N, Nealen MI, et al. Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): testosterone regulates AR expression. Blood 2000; 95: 2289-2296.
• Nagata Y, Yoshikawa J, Hashimoto A, et al. Proplatelet formation of megakaryocytes is triggered by autocrine estradiol. Genes Dev 2003; 17: 286428
• Goodrow GJ, L’Hommedieu GD, Gannon B, Sites CK. Predictors of worsening insulin sensitivity in postmenopausal women. Am J Obstet Gynecol 2006; 194: 355-361.
• Ranganath LR, Christofides J, Semple MJ. Increased mean platelet volume after oestrogen replacement therapy. Ann Clin Biochem 1996; 33: 555-560.
• Thijs A, van Baal WM, van der Mooren MJ, et al. Effects of hormone replacement therapy on blood platelets. Eur J Clin Invest 2002; 32: 613-618.
• Libby P. Molecular bases of the acute coronary syndromes. Circulation 1996; 91: 2844-2850.
• Wu KK, Thiagarajan P. Role of endothelium in thrombosis and hemostasis. Annu Rev Med 1996; 47: 315-3
• Santimone I, Di Castelnuovo A, De Curtis A, et al. White blood cell count, sex and age are major determinants of heterogeneity of platelet indices in an adult general population: results from the MOLISANI project Haematologica 2011; 96: 1180-1188.
• Suzuki S, Matsuno K, Kondoh M. Primary hemostasis during women's life cycle measured by Thrombostat 4000. Semin Thromb Hemost 1995; 21: 103Rank A, Nieuwland R, Nikolajek K, et al. Hormone replacement therapy leads to increased plasma levels of platelet derived microparticles in postmenopausal women Arch Gynecol Obstet 2012; 285: 1035-1041.
• Karagöz B, Bilgi O, Alacacıoğlu A, et al. Mean platelet volume increase after tamoxifen, but not after anastrazole in adjuvant therapy of breast cancer. Med Oncol 2009; 27:199-192.
• Teede HJ, McGrath BP, Turner A, Majewski H. Effects of oral combined hormone replacement therapy on platelet aggregation in postmenopausal women. Clin Sci (Lond) 2001; 100: 207-213.
• Poller L. Oral contraceptives, blood clotting and thrombosis. Br Med Bull 1978; 34: 151-156.
• Johnson M, Ramey E, Ramwell PW. Sex and age differences in human platelet aggregation. Nature 1975; 253: 253-355.
• Wattel E, Cambier N, Caulier MT, et al. Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases. Br J Haematol 1994; 87: 205.
• Sullivan PS, Jackson CW, McDonald TP. Castration decreases thrombocytopoiesis and testosterone restores platelet production in castrated BALB/c mice: evidence that testosterone acts on a bipotential hematopoietic precursor cell. J Lab Clin Med 1995; 125: 326-333.
• Kebapcilar L, Taner CE, Kebapcilar AG, Sari I. High mean platelet volume, low-grade systemic coagulation and fibrinolytic activation are associated with androgen and insulin levels in polycystic ovary syndrome. Arch Gynecol Obstet 2009; 280: 187-193.
• Martina V, Benso A, Gigliardi VR, et al. Short-term dehydroepiandrosterone treatment increases platelet cGMP production in elderly male subjects. Clin Endocrinol (Oxf) 2006; 64: 260-264.
• Li S, Li X, Li J, et al. Experimental arterial thrombosis regulated by androgen and its receptor via modulation of platelet activation. Thromb Res 2007; 121: 127-134.
• Munoz YC, Gomez GI, Moreno M, et al. Dehydroepiandrosterone prevents the aggregation of platelets obtained from postmenopausal women with type 2 diabetes mellitus through the activation of the PKC/eNOS/NO pathway. Horm Metab Res 2012; 44: 625-6